Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.320
-0.160 (-3.57%)
At close: Aug 24, 2026, 4:00 PM EDT
4.347
+0.027 (0.63%)
After-hours: Aug 24, 2026, 5:19 PM EDT
Camp4 Therapeutics Employees
Camp4 Therapeutics had 48 employees as of December 31, 2025. The number of employees decreased by 7 or -12.73% compared to the previous year.
Employees
48
Change (1Y)
-7
Growth (1Y)
-12.73%
Revenue / Employee
$87,833
Profits / Employee
-$2,234,250
Market Cap
271.09M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 48 | -7 | -12.73% |
| Dec 31, 2024 | 55 | -9 | -14.06% |
| Sep 30, 2024 | 53 | -11 | -17.19% |
| Jun 30, 2024 | 58 | - | - |
| Dec 31, 2023 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 161 |
| Entrada Therapeutics | 152 |
| Adagene | 128 |
| AC Immune | 122 |
| Lineage Cell Therapeutics | 77 |
| ALX Oncology Holdings | 48 |
| Surrozen | 44 |
| Eledon Pharmaceuticals | 33 |
CAMP News
- 8 days ago - Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c) - TheFly
- 8 days ago - Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler - TheFly
- 11 days ago - CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 11 days ago - Camp4 Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Camp4 Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - CAMP4 advances rare disease treatment for SYNGAP1 into human trials - CNBC
- 18 days ago - Camp4 Therapeutics Registration statement: Registration filing - Filings
- 20 days ago - CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - GlobeNewsWire